MorphoSys Investor Relations Material
Latest events
Q4 2023
MorphoSys
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from MorphoSys AG
Access all reports
Segment Data
Access more data
Revenue by
Source
Royalties
Licenses, Milestones and Other
Product Sales
Expenses by
Financials
MorphoSys AG is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. It offers MOR101 for the treatment of acute lymphoblastic leukemia. The company was founded in 1992 and is headquartered in Planegg, Germany.
Key slides for MorphoSys AG
Corporate Presentation
MorphoSys AG
Status Update
MorphoSys AG
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇩🇪 Germany